Maxim Positive on Omeros' (OMER) Omidria, OMS721; Reaffirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Omeros (OMER) Initiates Phase 3 for OMS721 Following FDA Meeting
March 8, 2016 7:03 AM ESTOmeros Corporation (NASDAQ: OMER) initiated its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome (aHUS) after meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS. The FDA has awarded OMS721 both orphan drug designation for the treatment of TMAs and fast-track status for the treatment of aHUS.
The OMS721 Phase 3 program will consist of one clinical trial a single-arm (i.e., no control arm), open-label... More
Omeros (OMER) Tops Q4 Loss Per Share of 52c
March 7, 2016 5:26 PM ESTOmeros (NASDAQ: OMER) reported Q4 EPS of ($0.52), may not compare to analyst estimate of ($0.55). Revenue for the quarter came in at $6.66 million versus the consensus estimate of $5.35 million.
For earnings history and earnings-related data on Omeros (OMER) click here.
... More